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Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies. Early diagnosis is 
critical for guiding the therapeutic management of ESCC. It is imperative to find more effective biomarkers of ESCC.
Methods: To identify novel biomarkers for esophageal squamous cell carcinoma (ESCC), specimens from 10 patients 
with ESCC were subjected to a comparative proteomic analysis. The proteomic patterns of ESCC samples and normal 
esophageal epithelial tissues (NEETs) were compared using two-dimensional gel electrophoresis. And differentially 
expressed proteins were identified using MALDI-TOF-MS/MS. For further identification of protein in selected spot, 
western blotting and immunohistochemistry were employed.
Results: Twelve proteins were up-regulated and fifteen proteins were down-regulated in the ESCC samples compared 
with the NEET samples. Up-regulation of galectin-7 was further confirmed by western blotting and 
immunohistochemistry. Furthermore, immunohistochemical staining of galectin-7 was performed on a tissue 
microarray containing ESCC samples (n = 50) and NEET samples (n = 10). The expression levels of galectin-7 were 
markedly higher in the ESCC samples than in the NEET samples (P = 0.012). In addition, tissue microarray analysis also 
showed that the expression level of galectin-7 was related to the differentiation of ESCC.
Conclusions: The present proteomics analysis revealed that galectin-7 was highly expressed in ESCC tissues. The 
alteration in the expression of galectin-7 was confirmed using a tissue microarray. These findings suggest that galectin-
7 could be used as a potential biomarker for ESCC.
Background
Esophageal carcinoma is one of the most malignant gas-
trointestinal cancers and is ranked the 6th leading cause
of cancer death worldwide [1]. Esophageal squamous cell
carcinoma (ESCC) is the predominant histological sub-
type of esophageal carcinoma in Asia [2]. The overall 5-
year survival rate of ESCC is less than 10% [3]. One of the
primary reasons for this high mortality rate is that ESCC
is often not detected until it has invaded surrounding
organs and is therefore at an advanced stage. Surgery is
inappropriate in 40-60% of patients due to unresectable
disease status, the presence of distant metastases, or high
operative risk [4]. Conventional chemotherapy and radio-
therapy treatments are also relatively ineffective [5]. The
odds of long-term survival are poor when the disease
extends through the esophageal wall or when it is diag-
nosed with widespread lymph node involvement. Early
diagnosis and exact histological grading of ESCC are
therefore critical for guiding the therapeutic management
of ESCC.
A biomarker is a molecule that indicates a pathological
alteration in physiology. Cancer biomarkers can provide
important information for cancer diagnosis and staging
and give guidance in many areas, such as cancer therapy
[6]. High-throughput and high-sensitivity proteomics
technology provides an effective approach for screening
novel cancer-specific biomarkers. Tissue-based pro-
teomic analyses directly relate protein biomarkers to dis-
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ease and have been widely used in the study of various
tumors [7-9]. In past years, molecules identified by pro-
teomics, such as pRB protein, tropomyosin isoform 4
(TPM4), prohibitin and periplakin [10-14] have been
reported as potential biomarkers for the diagnosis of
ESCC. However, most of these molecules require experi-
mental verification using clinical-scale sample sets before
clinical application. Thus, it is still imperative to find
more effective, clinically verified biomarkers of ESCC
[15].
Galectins are a family of β-galactoside-binding lectins
with diverse biological functions. Different galectin fam-
ily members have been reported to be show significantly
altered expression [16,17] and play important roles in
various types of cancer [18,19]. In a recent report, induc-
tion of galectin-1 expression by the human pituitary
tumor transforming gene (PTTG) promoted lymph node
metastasis in human ESCC [20]. Galectin-7, a member of
the galectin family initially identified in human epider-
mis, is a 15-kDa protein with a single carbohydrate recog-
nition domain [21,22]. Expression of galectin-7 is
restricted to stratified epithelial cells including the skin,
tongue, esophagus and Hassal's corpuscles in the thymus
[23]. The major functions of galectin-7 include regulation
of cell-cell and cell-matrix interactions, apoptosis and
immunity [16,24,25]. Growing evidence indicates that
galectin-7 plays an important role in cancer progression
[26-28]. Galectin-7 has been reported to function as an
important molecule in the dissemination and invasion of
lymphoma cells in human lymphoid malignancies [29]. It
is also involved in muscle infiltration of urothelial cancer
[30]. However, the expression pattern of galectin-7 in
ESCC tissue is still unknown.
In this study, a proteomics approach was used to ana-
lyze the different proteomic patterns in ESCC and NEET
samples. After comparing the expression patterns, differ-
entially expressed proteins between them were identified.
Among these proteins, galectin-7 was found to be highly
expressed in ESCC tissues. Confirmatory studies have
been done to examine the possibility of galectin-7 to be a
biomarker for ESCC.
Methods
Materials
The ESCC specimens were obtained from 10 patients
who undergone surgery in the thoracic surgery depart-
ment of Zhongshan Hospital. All ESCC patients under-
gone curative resection and were not treated with
neoadjuvant chemotherapy or radiotherapy. The clinical
staging was performed according to the tumor-node-
metastasis classification system. The overall clinico-
pathological data of the cases are listed in Table 1.
Matched normal mucosal tissues located at least 5 cm
away from the tumor margins were also included in this
study. Two additional groups of ESCC cases were used in
this work, 16 cases for immunohistochemistry, 50 cases
for tissue microarray, which included 12 cases catego-
rized as highly differentiated, 14 cases categorized as
moderately differentiated, 13 cases categorized as poorly
differentiated, and other cases in which pathologists did
not reach a consensus as to the degree of differentiation.
Freely tendered informed consent was obtained from all
patients. The study was approved by the local ethics com-
mittee of Zhongshan Hospital.
The IEF system (IPGphor), ImmobilineDryStrips (24
cm, pH 3-10NL) and CLEAN-UP Kits were purchased
from Amersham Biosciences. Iodoacetamide was
obtained from Sigma-Aldrich (St. Louis, MO). The MS
experiments were carried out using an ABI 4700 MALDI-
TOF/TOF mass spectrometer (Applied Biosystems,
Framingham, MA). Sequence-grade trypsin was obtained
from Promega (Madison, WI, USA), and the standard
peptide mixture used for calibration was obtained from
Applied Biosystems. All buffers were prepared with Milli-
Q water.
Sample preparation
Each tissue sample was crushed and ground in a mortar
containing liquid nitrogen. The resulting powder was
immediately suspended in a lysis buffer (7 M urea, 2 M
thiourea, 4% CHAPS, 65 mM DTT, 2% IPG buffer, and
trace cocktail protease inhibitor). After the solution was
vigorously stirred for 1 hr, the cell debris and insoluble
substances were removed by centrifugation at 100,000 g
for 45 min. Protein concentrations were determined
using a modified Bradford method [31]. The supernatant
was aliquoted and stored at -80°C for further use.
Two-dimensional electrophoresis (2-DE)
Seven batches of tissue samples were subjected to 2-DE.
2-DE was carried out according to the manufacturer's
instructions [32] with minor modifications. Briefly, 200
μg of protein sample was diluted to 450 μL with a rehy-
dration solution (7 M urea, 2 M thiourea, 0.2% DTT, 0.5%
[v/v] pH 3-10 IPG buffer and a trace of bromphenol blue)
and applied to IPG strips (24 cm, pH 3-10NL) in a 14-h
rehydration. Proteins were focused on an IPGphor IEF
system (Amersham Biosciences) for a total of 61 kVh. The
two-dimensional separation was performed on 12.5%
polyacrylamide gels with an Ettan DALT twelve appara-
tus (Amersham Biosciences) at 25°C. Protein spots in the
gels were visualized by silver staining as described by Yan
et al [33] with minor modifications.
Image analysis
Silver-stained 2-DE gels were scanned using a D2000
Uniscan scanner (Tsinghua Uniscan, Beijing, China) withZhu et al. BMC Cancer 2010, 10:290
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300-dpi resolution and analyzed using ImageMaster™ 2D
Platinum software (Version 5.0; Amersham Bioscience).
To guarantee the reliability of the results, the gel images
of seven batches of samples were imported to ImageMas-
ter™ 2D Platinum software simultaneously. Protein spots
were automatically detected. Individual spot volumes
were normalized against total spot volumes. Alignment
and matching of the spots were carried out by choosing
one gel as a reference and by manually selecting one com-
mon spot as a landmark. Two-sample t-tests were used to
analyze differences in protein expression between the
ESCC and NEET groups. Fold changes more than 1.5 and
P values less than 0.05 were considered statistically signif-
icant.
In-gel digestion and MS
The selected protein spots were excised from the gels and
incubated in a silver-destaining solution containing 30
mM potassium ferricyanide and 100 mM sodium thiosul-
fate (1:1) for 10 min at room temperature. The samples
were washed twice with Milli-Q water and once with 25
mM ammonium bicarbonate/50% acetonitrile (ACN).
The samples were then dehydrated in 100% (v/v) ACN
and dried in a speed-vacuum. After drying, the samples
were rehydrated on ice for 45 min in 2.5 μl of 25 mM
NH4HCO3 containing 10 ng/l sequencing-grade trypsin
(Promega, Madison, WI). The rehydrated gel spots were
digested for 4 hrs at 37°C. The peptide fragments were
extracted with 5% TFA and 2.5% TFA/50% ACN in suc-
cession. The supernatants were pooled, dried, and recov-
ered in 1.5 μL of 0.5% TFA. Finally, the digested peptide
samples were co-crystallized with an equal volume of sat-
urated matrix solution (CHCA in 0.1% TFA in H2O/ACN
[2:1]) on the MALDI sample target plate. Peptide mass
spectra were obtained with a MALDI-TOF/TOF mass
spectrometer (4700 Proteomics Analyzer, Applied Bio-
systems).
The protein spots were identified by MS and MS/MS as
described by Tian et al [34]. Prior to real sample acquisi-
tion, six external standards (mass standard kit for the
4,700 proteomics analyzer calibration mixture, Applied
Biosystems) were used to calibrate each spectrum to a
mass accuracy of within 5 ppm for the MS Reflector Posi-
tive Operating Mode or within 10 ppm for the MS-MS 1
KV Positive Operating Mode. A combined database
search of MS and MS/MS measurements was performed
using GPS Explorer™ software (Version 3.5; Applied Bio-
systems) and MASCOT software (Version 2.0; Matrix
Science, London, UK). Searches were performed with
carbamidomethylation of cysteine and oxidation of meth-
ionine as variable modifications. One trypsin miscleavage
was allowed. The peptide mass tolerance and fragment
mass tolerance were set to 50 ppm and ± 0.1 Da, respec-
tively. Peptide mixtures that yielded statistically signifi-
cant search scores (> 95% C.I., equivalent to MASCOT
expected value < 0.05) and accounted for the majority of
ions present in the mass spectra were defined as positive
identifications.
Western blotting
For validation experiments, a new set of tissue samples
was collected for immunoblotting analysis of galectin-7.
All protein samples for validation were separated by SDS-
PAGE with 20 μg protein per lane and transferred onto a
PVDF membrane (Millipore) in transfer buffer (pH 11.0,
25 mM Tris, 0.2 M glycine, 20% [v/v] methanol) for 45
min at 1.5 mA/cm2 on a semidry electroblotter (Bio-Rad).
After being blocked with 1% skim milk for 1 hr at 25°C,
galectin-7 was detected by incubating the samples with a
goat polyclonal anti-galectin-7 antibody at a 1:300 dilu-
tion (R&D Systems, Minneapolis, MN) overnight at 4°C.
Table 1: Clinicopathological data of the 10 ESCC cases
Sample No. Age Gender Site Pathological grade Size (cm) Lymphatic 
invasion
TNM stage
1 58 Male Upper Moderately differentiated 3 Negative II
2 67 Female Middle Moderately differentiated 5 Positive III
3 55 Male Middle Well differentiated 2 Negative I
4 62 Male Middle Moderately differentiated 2 Negative I
5 62 Male Upper Moderately differentiated 2.5 Negative II
6 52 Male Middle Poorly differentiated 4 Negative II
7 61 Male Middle Moderately differentiated 3 Negative II
8 55 Female Lower Poorly differentiated 6 Positive IV
9 70 Male Lower Moderately differentiated 5 Positive III
10 53 Male Middle Poorly differentiated 3 Positive IIZhu et al. BMC Cancer 2010, 10:290
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Horseradish peroxidase-conjugated rabbit anti goat Ig at
a 1:3,000 dilution (AMS Biotechnology, Oxon, UK) was
used as a secondary antibody. The immunoblots were
developed using ECL detection reagent (Pierce Chemi-
cal).
Immunohistochemistry
Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded tissue sections using a standard
immunohistochemical technique. Four-micrometer-thick
tissue sections were deparaffinized in xylene, rehydrated
in a graded ethanol series and treated with an antigen
retrieval solution (10 mM sodium citrate buffer; pH 6.0).
The sections were incubated with a goat polyclonal anti-
galectin-7 antibody (dilution 1:125) overnight at 4°C and
then incubated with a 1:1,000 dilution of biotinylated sec-
ondary antibody, followed by avidin-biotin peroxidase
complex (DAKO), according to the manufacturer's
instructions. Finally, tissue sections were incubated with
3,3'-diaminobenzidine (Sigma-Aldrich) until a brown
color developed, and the sections were then counter-
stained with Harris modified hematoxylin. For the nega-
tive controls, the primary antibodies were omitted.
Tissue microarray
The tissue microarray slides (Shanghai Biochip Company,
Ltd., Shanghai, China) contained 120 formalin-fixed, par-
affin-embedded tissue samples, including 50 ESCC tis-
sues, 10 NEET samples. Each sample had two sample
dots. Immunohistochemistry for galectin-7 was per-
formed using the avidin-biotin complex method (ABC;
Vector Laboratories, Burlingame, CA), including heat-
induced antigen-retrieval procedures. Incubation with
polyclonal antibodies against galectin-7 (1:100 dilution;
R&D Systems, Minneapolis, MN) was done at 48°C for 18
hours. Fourteen negative controls were treated identically
but with the primary antibody omitted.
Evaluation of galectin-7 expression
The German immunohistochemical scoring (GIS) system
was applied to estimate galectin-7 expression. The GIS
system is a semiquantitative scoring system in which the
final immunoreaction score is expressed as the product of
the intensity and quantity scores. The extent percentage
of positive cells was graded as follows: 0, negative; 1, <
10% positive cells; 2, 11% to 50% positive cells; 3, 51% to
80% positive cells; 4, > 80% positive cells. The staining
intensity was graded as follows: 0, negative; 1, weakly pos-
itive; 2, moderately positive; and 3, strongly positive. GIS
score ≥ 6 was defined as high expression. GIS score < 6
was defined as low expression. All staining was indepen-
dently evaluated by three different pathologists who were
blinded to patient outcomes. Statistical analysis of GIS
scores was done using SigmaPlot software. P values less
than 0.05 were considered statistically significant.
Results
2-DE proteome maps of NEET and ESCC specimens
The proteomic profiles of the ESCC and NEET samples
were examined using 2-DE. After silver nitrate staining,
2-DE images with high resolution and reproducibility
were obtained. Representative 2-DE images are shown in
Figure 1. To ensure reliability and reproducibility, seven
batches of tissue samples were subjected to proteomic
analysis using ImageMaster 2D Platinum Version 5.0
software and fourteen gels were generated. Twenty-seven
protein spots had significantly different expression pat-
terns between the two groups (> 1.5-fold change, P < 0.05;
Figure 1). Relative to the NEET group, the expression lev-
els of 12 protein spots were markedly increased and 15
protein spots were decreased in the ESCC group. The
zoom-in and 3D quantified views showed some represen-
tative differentially expressed protein spots between the
two types of tissues (Figure 2A). The statistical analysis of
the volumes (% volume) of these spots from seven
batches of tissue samples is shown in Figure 2B.
Figure 1 Representative 2-DE protein profiles. 2-DE protein pro-
files of NEET (A) and ESCC samples (B). Proteins were separated on the 
basis of pI (X-axis) and molecular mass (Y-axis). A total of 250 μg protein 
was separated using 24 cm pH 3-10NL IPG strips (cup-loading method) 
and 12.5% SDS-PAGE. Proteins were visualized by silver staining. Differ-
entially expressed proteins are indicated with black circles. These pro-
teins were identified by MALDI-TOF/TOF MS, as summarized in 
Additional file 1.Zhu et al. BMC Cancer 2010, 10:290
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Identification of differentially expressed proteins using 
MALDI-TOF/TOF mass spectrometry and functional 
exploration of candidate proteins
To characterize the differentially expressed proteins, the
2-DE spots were excised from the silver-stained gels and
analyzed by MALDI-TOF mass spectrometry. The pep-
tide mass fingerprints (PMF) of the differentially
expressed proteins were acquired in the MS Reflector
Positive Operating Mode and then subjected to SwissProt
database searching using GPS Explorer™ software. To fur-
ther confirm the MS identification results, four peaks
with the strongest signals in the MS spectra were auto-
matically selected and subjected to MS/MS analysis. MS
and MS/MS identification of each differentially expressed
protein from different batches of 2-DE gels were repeated
at least three times. As a representative example, the PMF
and MS/MS spectra of galectin-7 are illustrated in Figure
3. The matched amino acid sequences of galectin-7 are
underlined. Three precursor peptides of m/z 857.4628,
1399.7379 and 2511.1833 were confirmed as the tryptic
peptides of galectin-7. The amino acid sequences of these
peptides identified by MS/MS were "76GPGVPFQR83",
"100AVVGDAQYHHFR111", and "33FHVNLLCGEEQGSD
AALHFNPR54". Additional file 1 (Identification of pro-
teins differentially expressed in esophageal cancer speci-
mens by MALDI-TOF MS and MS/MS) summarizes the
identified proteins and their gene names, Swiss-Prot
accession numbers, theoretical molecular weights/pI val-
Figure 2 Comparative analysis of representative proteins with altered expression patterns in NEET and ESCC cells. (A) Magnified comparison 
maps and quantified 3D views. (B) Statistical analyses of the protein spots.Zhu et al. BMC Cancer 2010, 10:290
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ues, mascot scores, peptide counts, coverage (%),
sequence confirmation by MS/MS and MS/MS scores.
The expression patterns of differentially expressed pro-
teins in esophageal cancer specimens and their biological
functions are shown in additional file 2: Expression pat-
terns of differentially expressed proteins in esophageal
cancer specimens and their biological functions. Regula-
tory factors and statistics are also included in additional
file 2. The identified proteins were classified into 8 func-
tional categories based on their molecular functions and
biological processes according to the KEGG and ExPasy
http://www.expasy.org/sprot/ databases (See additional
file 3: Functional classification of proteins). Approxi-
mately 27% of the proteins are involved in metabolism,
including energy, carbohydrate, nucleotide and lipid
metabolism. Cell growth and death (20%) and cytoskele-
tal (19%) functions accounted for the second and third
categories of proteins, respectively. Proteins involved in
Figure 3 Identification of galectin-7 by MALDI-TOF/TOF mass spectrometry. (A) Peptide mass fingerprints of galectin-7 are shown. Matched 
peptide peaks are labeled with mass values, and the sequences of precursor peptides with m/z 857.4628, 1399.7379 and 2511.1833 were confirmed 
using MALDI-TOF MS/MS. (B) Amino acid sequences of galectin-7. Matched peptides are underlined.Zhu et al. BMC Cancer 2010, 10:290
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signal transduction (11%), folding (9%), transcription
(8%) and transport (2%) were also identified.
Validation by western blotting and immunohistochemistry
The proteins identified by mass spectrometry such as
annexin A1, tropomyosin, profiling 1, translationally con-
trolled tumor protein and serpin B3 have been previously
reported to be altered in malignancies [14,35-39]. How-
ever, the expression level of most of them have not been
studied in ESCC. Among the differentially expressed pro-
teins in ESCC, we decided to focus on further confirming
the expression patterns of Glectin-7, whose expression
levels have not been well studied in human esophageal
cancers and whose change in its expression could poten-
tially be served as a marker for ESCC. To confirm the dif-
ferential expression pattern of galectin-7, additional
samples were examined by western blotting and immu-
nohistochemistry. Consistent with the 2-DE data, the
western blotting results (See additional file 4: Western
blotting results of galectin-7 expression in several pairs of
ESCC and NEET samples) showed elevated expression
levels of galectin-7 in the ESCC samples relative to the
NEET samples (Figure 4B).
Immunohistochemical staining also showed that galec-
tin-7 is highly expressed in ESCC tissues relative to NEET
samples. Furthermore, the expression of galectin-7 was
distributed in the cytoplasm, nuclei and membranes of
ESCC cells, whereas it was distributed primarily in only
the nuclei of NEET cells (Figure 4C). The sub-cellular
localization and expression of galectin-7 were examined
by immunofluorescence staining in four ESCC cell lines
as well (See additional file 5: Sub-cellular localization of
galectin-7 in four ESCC cell lines). These results, taken
together with the proteomics observations, suggest that
galectin-7 is up-regulated in ESCC tissues, which further
support that galectin-7 could be served as a potential
marker for ESCC.
Tissue microarray
To further investigate the clinical significance of the dif-
ferential expression of galectin-7 in ESCC tissues, we
extended our studies by performing tissue microarray
evaluations on a larger patient population. Figure 5 dis-
plays representative images of immunostaining for galec-
tin-7. In 10 NEET samples, negative (n = 2, 20%), very
weak (n = 7, 70%) or weak (n = 1, 10%) expression of
galectin-7 was detected. In contrast, high expression of
galectin-7 was detected in 28 of 50 (56.0%) ESCC sam-
ples. The fold difference of galectin-7 expression in ESCC
versus NEET samples was 2.5 (P = 0.012) (Figure 5).
In 50 cases of ESCC, 12 cases were diagnosed as being
well differentiated, 14 were diagnosed as moderately dif-
ferentiated and 13 were diagnosed as poorly differenti-
ated. We excluded the analysis of 6 cases of carcinoma in
situ and 5 cases in which pathologists did not reach a
consensus as to the degree of differentiation. Two groups
divided by high or low expression were considered for
statistical analysis. The most differentiated (grade I)
ESCC samples showed a strong positive signal for galec-
tin-7. Conversely, poorly differentiated (grade III) ESCC
samples showed relatively low galectin-7 expression. A
statistically significant association was observed between
galectin-7 expression level and the differentiation of
human ESCC (P = 0.045) (Table 2). Taken together, these
results indicate that galectin-7 is up-regulated in ESCC
and that its expression is related to the differentiation of
ESCC.
Discussion
This study was designed to isolate and identify ESCC bio-
markers using proteomic tools. Using 2-DE and mass
spectrometry, we have successfully identified 27 proteins
with different expression patterns in ESCC tissues. In
previous ESCC proteomics studies, several differentially
expressed proteins such as transgelin and tropomyosin
were identified [14]. Among these 27 proteins, there are
also several proteins we are interested, and may be fur-
ther investigated, such as galectin-7, PEBP1, profilin1,
TCTP and triosephosphate isomerase. Among them,
galectin-7 was found to be rarely reported differentially
expression in ESCC before. Besides, some reports
showed that galectin-7 expression altered during the
tumour progression in some kinds of carcinomas
[27,29,40]. So, among these differentially expressed pro-
teins, galectin-7 was selected for further verification and
investigation.
There are several reports of galectin-7 expression in
human cancers [30,41]. However, these reports suggest
conflicting roles of galectin-7 in cancer progression [14];
galectin-7 appears to have dual roles, with anti- and pro-
malignant features, and different expression levels in dif-
ferent cancers. Galectin-7 expression can be induced by
p53 transfection in a human colon carcinoma cell line.
Therefore, galectin-7 has been designated p53-induced
gene 1 (PIG1) [42]. The anti-tumor roles of galectin-7 are
associated with induction of apoptosis [43] or inhibition
of cell proliferation [44]. In contrast, other reports have
demonstrated that galectin-7 is up-regulated in other
cancers such as hypopharyngeal squamous cell carci-
noma [27]. One mechanism of the pro-tumor role of
galectin-7 may involve induction of MMP-9, which plays
an important role in cancer progression and metastasis
[45]. Although proteomics has been used previously to
characterize the molecular background of ESCC, this is
the first report of an up-regulation of galectin-7 in ESCC
tissues. Furthermore, the up-regulation was confirmed byZhu et al. BMC Cancer 2010, 10:290
http://www.biomedcentral.com/1471-2407/10/290
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Figure 4 Expression of galectin-7 is up-regulated in ESCC tissues relative to NEET tissues. (A) The magnified comparison maps, quantified 3D 
views and statistical analyses of galectin-7 expression in NEET and ESCC samples. (B) Representative samples of ESCC and NEET were resolved on 10% 
polyacrylamide gels and immunoblotted with an anti-galectin-7 antibody and a β-actin antibody as a loading control. The intensity of each band was 
measured with GraphPad Prism 4.0 software, and relative galectin-7 protein levels between ESCC and NEET samples were normalized against those 
of β-actin. The expression of galectin-7 was increased in tumor tissues. The difference in galectin-7 expression between ESCC and NEET samples was 
assessed using Student's t-test (*P < 0.05) for unpaired values. (C) Immunohistochemical analysis of galectin-7 expression in ESCC. Galectin-7 displayed 
positive staining in ESCC samples that was much stronger than the staining in non-neoplastic tissue. In normal esophageal epithelial tissues, galectin-
7 is localized primarily to the nucleus. Expression of galectin-7 was detected ubiquitously in the cytoplasm, nuclei and membranes of ESCC cells. Im-
ages in the left panel were taken under 200× magnification; the right panel images are 400× magnifications of the same sections depicted on the left.Zhu et al. BMC Cancer 2010, 10:290
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western blotting and immunohistochemistry of clinical
sample sets. Due to the epithelial of esophagus is one of
restricted regions expressing galectin-7 [23], it is possible
that the different expression pattern has special role in
the progression of ESCC. Collectively, these results indi-
cate that galectin-7 is a potential biomarker for ESCC.
We found that the level of galectin-7 expression was
related to the degree of ESCC differentiation. The well-
differentiated (grade I) ESCC samples showed a stronger
positive signal for galectin-7 compared with poorly dif-
ferentiated (grade III) ESCC samples. Because galectin-7
acts downstream of the p53 anti-tumor gene, up-regula-
tion of galectin-7 expression in the early stages of ESCC
progression may be a mechanism of organ self-protec-
tion. Consistent with our findings, other reports have
indicated that galectin-7 has different expression pattern
in the different degree of tumor differentiation in bladder
squamous cell carcinoma [46] and glyctin-7 has both
anti- and pro-malignant characteristics at different stages
in the progression of thyroid cancer [40]. Because one of
the main reasons for the high mortality rate of ESCC is
that it is not detected until it has invaded surrounding
organs and is at an advanced stage, the special up-regula-
tion of galectin-7 in ESCC may be useful as a diagnosis
marker of ESCC.
Figure 5 Tissue microarray analysis of galectin-7 expression. (A) Overview of the tissue microarray. (B) Representative example of galectin-7 ex-
pression in NEET (100×) and in ESCC tissues (100×). (C) Expression patterns of galectin-7 in NEET and ESCC were analyzed using the GIS score system. 
The differences in galectin-7 expression levels in ESCC and NEET were assessed by the Student's t-test (*P < 0.05) for unpaired values.Zhu et al. BMC Cancer 2010, 10:290
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In this study, we found that galectin-7 was primarily
localized in the nuclei of NEET cells, whereas it was dis-
tributed throughout the cytoplasm, nuclei and mem-
branes of ESCC cells. The intracellular localization of
certain proteins may be associated with tumor progres-
sion. For example, nuclear localization of galectin-7 was
associated with the initiation of tumorigenesis in laryn-
geal squamous cell carcinomas [27]. Additionally, galec-
tin-3 was localized to the nuclei of ESCC cells [47]. These
results suggest that tumor progression of ESCC may be
associated with a translocation of galectin-7 from the
nucleus to the cytoplasm.
Conclusions
Using proteomic analysis, we have identified galectin-7 as
a potential biomarker of ESCC. Furthermore, we have
confirmed the alteration in the expression of galectin-7
using a tissue microarray. These results strongly suggest
that galectin-7 is involved in the development of ESCC
and could potentially be served as a marker for ESCC.
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Table 2: Comparison of ESCC differentiation degree with galectin-7 expression
Expression level Differentiation degree P value
well moderately poorly
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h i g h 893
High expression levels correspond to tumors with either intense homogeneous or intense inhomogeneous Gal-7-dependent staining signals. 
Low expression levels correspond to tumors with either weak homogeneous staining signals or no detectable Gal-7 signal.Zhu et al. BMC Cancer 2010, 10:290
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